Skip to content
value.today

Exosome Theranostics, Inc.

🇺🇸 New York, New York, USABiotechnologyFounded 2008
Total raised
$91 M
6 rounds on record
Latest round
$30 M
Jun 2017
First round on record
Apr 2010
Today
Private
No later event on record

Funding rounds

6 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Exosome Theranostics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2017$30 MNo. 6$10 to $50 million

Exosome Theranostics, Inc.: Raise no. 6, Jun 2017

Investors in this round

43 investors had bought by the notice of Jul 6, 2017: 43 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Boyce · Executive Officer, Director
  • Thomas McLain · Executive Officer
  • William Kelly · Executive Officer
  • Geert-Jan Mulder · Director
  • Joseph Slattery · Director
  • Kapil Dhingra · Director
  • Peter Johann · Director
  • Steven Soignet · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William Kelly, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 6, 2017. Read the notice at the SEC.

equitySEC
Aug 2015$16 MNo. 5$10 to $50 million

Exosome Theranostics, Inc.: Raise no. 5, Aug 2015

Investors in this round

9 investors had bought by the notice of Sep 15, 2015: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$16 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Thomas McLain · Executive Officer, Director · Chief Executive Officer and Director of Issuer
  • William Kelly · Executive Officer · Chief Financial Officer and Secretary of Issuer
  • Geert-Jan Mulder · Director
  • Joseph Slattery · Director
  • Kapil Dhingra · Director
  • Peter Johann · Director
  • Steven Soignet · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas McLain, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 15, 2015. Read the notice at the SEC.

equity, optionsSEC
Jun 2015$1 MNo. 4Under $2 million

Exosome Theranostics, Inc.: Raise no. 4, Jun 2015

Investors in this round

12 investors had bought by the notice of Jul 6, 2015: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $2 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Thomas McLain · Executive Officer, Director · Chief Executive Officer and Director of Issuer
  • William Kelly · Executive Officer · Chief Financial Officer and Secretary of Issuer
  • Geert-Jan Mulder · Director
  • Joseph Boystak · Director
  • Joseph Slattery · Director
  • Kapil Dhingra · Director
  • Peter Johann · Director
  • Steven Soignet · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas McLain, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 6, 2015. Read the notice at the SEC.

equity, optionsSEC
Mar 2014$27 MNo. 3$10 to $50 million

Exosome Theranostics, Inc.: Raise no. 3, Mar 2014

Investors in this round

26 investors had bought by the notice of Mar 13, 2014: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$27 M of $40 M offered; $13 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$896,992
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • James McCullough · Executive Officer, Director
  • Sara Barrington · Executive Officer
  • Dhingra Kapil · Director
  • Geert-Jan Mulder · Director
  • Joseph Boystak · Director
  • Joseph Slattery · Director
  • Peter Johann · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Leerink Partners LLC (CRD 39011) · Boston, MassachusettsSold in CT, IL, MA, NJ, NY
  • Hudson Capital Advisors BD LLC (CRD 132424) · Santa Monica, CaliforniaSold in CT, NY

Remarks in the notice

  • On the amounts: “The amount sold shown Item 13 and number of investors shown in Item 14 include $13,849,959 from 5 non-US investors.”
  • On the use of proceeds: “The Issuer will use proceeds for general working capital purposes which includes payments to its executive officers and other employees in the ordinary course of business”

Signed by James McCullough, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 13, 2014. Read the notice at the SEC.

equitySEC
Aug 2012$7 MNo. 2$2 to $10 million

Exosome Theranostics, Inc.: Raise no. 2, Aug 2012

Investors in this round

2 investors had bought by the notice of Aug 15, 2013: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $9 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • James McCullough · Executive Officer, Director
  • Sara Barrington · Executive Officer
  • Dhingra Kapil · Director
  • Geert-Jan Mulder · Director
  • Joseph Boystak · Director
  • Joseph Slattery · Director
  • Peter Johann · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “The Issuer will use proceeds for general working capital purposes which includes payments to its executive officers and other employees in the ordinary course of business”

Signed by James McCullough, Chief Executive Officer. Source: SEC Form D and 3 amendments, newest notice filed Aug 15, 2013. Read the notice at the SEC.

debt, optionsSEC
Apr 2010$10 MNo. 1$2 to $10 million

Exosome Theranostics, Inc.: Raise no. 1, Apr 2010

Investors in this round

10 investors had bought by the notice of May 12, 2010: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $23 M offered; $13 M still to sell
Smallest investment taken
$25,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Convertible Preferred Stock and Warrants
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
$270,000
Finders' fees
none
Paid to its own people
$1,170,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Greg Zdechlik · Executive Officer
  • James McCullough · Executive Officer, Director
  • Sara Barrington · Executive Officer
  • Wayne Comper · Executive Officer
  • Geert-Jan Mulder · Director
  • Georg Nebgen · Director
  • Joseph Boystak · Director
  • Peter Johann · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Hudson Capital Advisors BD LLC (CRD 132424) · Los Angeles, CaliforniaSold in CA, IL, MA, NY

Remarks in the notice

  • On fees: “In addition to cash consideration, a warrant to purchase 17,906 shares of common stock of the company was also issued”
  • On the amounts: “Future Investments are based on the company achieving specified milestones.”

Signed by James McCullough, Chief Executive Officer. Source: SEC Form D, newest notice filed May 12, 2010. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Exosome Theranostics, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2017).

    SEC Form D · Jul 2017

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2017

That is all the official record says: Exosome Theranostics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Exosome Theranostics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 43 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Exosome Theranostics, Inc.
NameRoleNamed in
John BoyceExecutive officerJul 2017
Thomas McLainExecutive officerJul 2017
William KellyExecutive officerJul 2017
James McCulloughExecutive officerMar 2014
Sara BarringtonExecutive officerMar 2014
David OkronglyExecutive officerJun 2013
Wayne ComperExecutive officerJun 2013
Greg ZdechlikExecutive officerMay 2010
Geert-Jan MulderDirectorJul 2017
John BoyceDirectorJul 2017
Joseph SlatteryDirectorJul 2017
Kapil DhingraDirectorJul 2017
Peter JohannDirectorJul 2017
Steven SoignetDirectorJul 2017
Thomas McLainChief Executive Officer and Director of IssuerSep 2015
Joseph BoystakDirectorJul 2015
Dhingra KapilDirectorMar 2014
James McCulloughDirectorMar 2014
Georg NebgenDirectorMay 2010